Communiqués Voyager Therapeutics, Inc.

Actions

VYGR

US92915B1061

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 11/07/2024			Varia. 5j.	Varia. 1 janv.
8,94 ^USD	+10,64 %		+15,65 %	+5,92 %

13/06	Voyager Therapeutics, Inc. nomme Nathan Jorgensen au poste de directeur financier et de directeur comptable, à compter du 8 juillet 2024 au plus tard.	CI
16/05	Voyager Therapeutics, Inc. annonce le dosage des premiers participants à l'essai à dose unique ascendante de VY-TAU01 pour le traitement de la maladie d'Alzheimer	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	10/07	AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	09/07	AQ
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences	13/06	AQ
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer	13/06	AQ
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease	16/05	AQ
Voyager Therapeutics: Q1 Earnings Snapshot	13/05	AQ
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results	13/05	AQ
Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	09/05	AQ
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	08/05	AQ
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast	06/05	AQ
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	22/04	AQ
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	16/04	AQ
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	16/04	AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	27/03	AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	26/03	AQ
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer	13/03	AQ
Voyager Therapeutics: Q4 Earnings Snapshot	28/02	AQ
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	28/02	AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	27/02	AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Voyager Therapeutics, Inc.

Actions

VYGR

US92915B1061

Communiqués

Filtres